Fig. 3 |. No significant elevation in serum cytokine levels after CD19-BBz(86) CAR T cell infusion.

a, Serum kinetics of a panel of cytokines in 11 patients who received infusions with high doses of CD19-BBz(86) CAR T cells (total of 2–4 × 10⁸ CAR T cells per patient), as determined by Luminex multiplex assay (R&D Systems). Of the 11 patients, 6 achieved complete remission, 2 achieved partial remission and 3 had progressive disease. Horizontal lines denote median values. b, Serum levels of CRP in patients who achieved remission (complete or partial; n = 8) or had progressive disease (n = 3) after CAR T cell infusion. ‘−1 to 0’, 1 d before or the same day as CAR T cell infusion. Horizontal lines denote median values. c, Serum granzyme levels were significantly higher in patients who achieved complete or partial remission (n = 8) than in patients who had progressive disease (n = 3) 1 week after CAR T cell infusion. P values were calculated by two-tailed Student’s t tests. Horizontal lines denote median values. d, Flow cytometry analysis showing in vivo expansion of tEGFR⁺ CD19-BBz(86) CAR T cells in the peripheral blood of representative patient BZ014, who achieved a PR.